As the NAD+ level is reduced in humans with various pathological conditions, including diabetes, inflammation, aging, rheumatoid arthritis, and neurodegenerative disorders [1,9,10,11,12], the inhibition of CD38 has become a therapeutic strategy for treating these pathological conditions [1,3,4,5,13]. This evidence concerns the gene CD38 and rheumatoid arthritis.